Global Hepatitis C Drugs Market Research Report- Forecast to 2027

Global Hepatitis C Drugs Market Information, By Drug Class (Anti-Viral, Immuno-modulators and others), By Medicine System (Allopathic, Alternative and Others), By Route of Administration (Oral, Injectable and others) and By End User (Hospitals and Private) - Forecast Till 2027

ID: MRFR/Pharma/1848-HCR | February 2021 | Region: Global | 100 pages

Market Synopsis of Global Hepatitis C Drugs Market:


Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc.


Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepatitis C is caused by hepatitis C virus and affects between 130–150 million people globally every year of which approximately 700 000 people die from hepatitis C-related liver diseases. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.


The market for hepatitis C is driven by factors such as disease prevalence, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc.


However the restraints are overwhelming such as self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc. Thus the market in developed regions appears to reach a plateau as the number of people affected is not rising in developed regions. The reevaluation of hepatitis C strategy by companies such as Boehringer Ingelheim and its decision to refrain from moving forward in hepatitis C research also is an indication of stagnancy in developed region markets.


The market is also unitary with a few dominant players such as Gilead with a few brands such as Sovaldi, Harvoni etc are leading the market. The development pipeline is however strong in the vaccine segment and it is expected that a vaccine will make its foray in the near future as happened with other forms of hepatitis.


Taking into consideration all factors the market for global hepatitis drugs was estimated to rise from $18700 million to $22721.1 million by the end of forecasting period reflecting a sluggish CAGR of 3.3%.


Study Objectives Global Hepatitis C Drugs Market:



  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global Hepatitis C drugs market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by drug class (anti-viral, immuno-modulators and others), by medicine system (allopathic, alternative and others), by route of administration (oral, injectable and others) and by end user (hospitals and private)

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.


 Global Hepatitis C Drugs Market, by Route of Administration, 2015 (%): Global Hepatitis C Drugs Market, by Route of Administration, 2015

  Intended Audience



  • Hepatitis C Drugs Manufacturers

  • Hepatitis C Drugs Suppliers

  • Private Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Government Research Laboratories

  • Contract Manufacturing Organizations


Key Players for Global Hepatitis C Drugs Market:

Some of the key players in this market are: Gilead sciences Inc., Abbvie Inc, Johnson & Johnson, Merck & co. Inc., Glaxosmithkline plc, Novartis AG, Bristol-Myers Squibb, Hoffmann-la Roche ltd. and others.


Segments:


Global hepatitis c drugs market has been segmented on the basis of drug class which comprises anti-viral, immuno-modulators and others. On the basis of medicine system; market is segmented into allopathic, alternative and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of end user the market is segmented into hospitals and private.


Regional Analysis of Global Hepatitis C Drugs Market:


Globally America is the largest market for Hepatitis C drugs. Europe is the second-largest market for Hepatitis C drugs. The developed regions market is expected to remain stagnant and even may show negative CAGR due to falling patient’s number. Thus market of developing nations however will show moderate growth and is expected to catch on the developed regions. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global hepatitis C market.


The report for Global Hepatitis C Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 22721.1 Million
  CAGR   3.3% (2016-2022)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Class, Medicine System, Route of Administration and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Gilead sciences Inc., Abbvie Inc, Johnson & Johnson, Merck & co. Inc., Glaxosmithkline plc, Novartis AG, Bristol-Myers Squibb, Hoffmann-la Roche ltd.
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments
  Key Market Drivers   disease prevalence, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations


Frequently Asked Questions (FAQ) :


hepatitis C drugs market is projected grow at approximately 3.3% CAGR during the assessment period (2016-2022).

Consistent healthcare advancement initiatives and awareness efforts and increasing funding support for R&D from public & private sectors are the major tailwinds pushing the growth of the global hepatitis C drugs market.

North America holds the largest share in the global hepatitis C drugs market, followed by Europe and the Asia Pacific, respectively.

Johnson & Johnson, Gilead Sciences Inc., GSK, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Novartis AG, AbbVie Inc., and Merck & Co. Inc., are some of the major players operating in the hepatitis C drugs market.

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s five forces model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Global Hepatitis C Drugs market, by Drug Class

5.1 Introduction

5.2 Anti-Viral

5.3 Immuno-modulators

5.4 Others

6 Global Hepatitis C Drugs Market, By Medicine System

6.1 Introduction

6.2 Allopathic

6.3 Alternative

6.4 Others

7 Global Hepatitis C Drugs Market, By Route of Administration

7.1 Introduction

7.2 Oral

7.3 Injectable

7.4 Others

8 Global Hepatitis C Drugs Market, By End User

8.1 Introduction

8.2 Hospitals

8.3 Private

9 Global Hepatitis C Drugs market, by Regions

9.1 Introduction

9.1.1 Americas

9.1.1.1 North America

9.1.1.2 South America

9.1.2 Europe

9.1.2.1 Germany

9.1.2.2 France

9.1.2.3 UK

9.1.2.4 Italy

9.1.2.5 Spain

9.1.2.6 Rest of Europe

9.1.3 Asia Pacific

9.1.3.1 Japan

9.1.3.2 China

9.1.3.3 India

9.1.3.4 Republic of Korea

9.1.3.5 Rest of Asia Pacific

9.1.4 Middle East & Africa

10 Company Landscape

10.1 Introduction

10.1.1 Mergers Acquisitions

10.1.2 Collaborations

10.1.3 Release/New Product Launches

10.1.4 Other (Expansion, Updates, Partnership)

11 Company Profile

11.1 Gilead sciences Inc.

11.1.1 Company Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Merck & Co.

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financials

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Novartis International AG

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financials

11.3.4 Key Developments

11.3.5 SWOT Analysis

11.4 Abbvie Inc

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financials

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.5 F. Hoffmann La Roche Ltd.

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financials

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Bristol-Myers Squibb

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financials

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Johnson & Johnson

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7 Glaxosmithkline plc

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

11.8.1 Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

12 Others

13 Appendix

List of Tables

TABLE 1 GLOBAL HEPATITIS C DRUGS MARKET, 2020-2027 (USD MILLION)

TABLE 2 GLOBAL HEPATITIS C DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL HEPATITIS C DRUGS MARKET, BY MEDICINE SYSTEM, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL HEPATITIS C DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL HEPATITIS C DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL HEPATITIS C DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL HEPATITIS C DRUGS MARKET, BY DRUG CLASS

FIGURE 4 GLOBAL HEPATITIS C DRUGS MARKET, BY MEDICINE SYSTEM

FIGURE 5 GLOBAL HEPATITIS C DRUGS MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 6 GLOBAL HEPATITIS C DRUGS MARKET, BY END USER

FIGURE 7 GLOBAL HEPATITIS C DRUGS MARKET, BY REGION

FIGURE 8 GLOBAL HEPATITIS C DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)